Estradiol Vaginal Cream 30gm 0.03%
Estradiol Vaginal Cream 30gm 0.03% is part of a prescriber-directed hormone or endocrine protocol. It should be selected based on symptoms, diagnosis, labs when appropriate, route preference, contraindications, and ongoing monitoring.
Estradiol Vaginal Cream 30gm 0.03% is a 30-gram intravaginal cream tube containing 0.03% estradiol (0.3 mg estradiol per gram) for the local treatment of genitourinary syndrome of menopause. The 30 g quantity provides an approximately 30-application supply at 1 gram per dose, or correspondingly more applications at smaller doses as directed by the prescribing clinician. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded vaginal preparation that is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Estradiol 0.03% (0.3 mg/g), 30gm tube | Bioidentical estrogen; locally applied to vaginal mucosa to restore epithelial integrity, lubrication, and pH via ERα/ERβ signaling in genitourinary tissue, with limited systemic absorption. |
Route: Intravaginal — using calibrated applicator or as directed.
- Insert the prescribed gram amount intravaginally at bedtime or as directed.
- Remain supine briefly after insertion to maximize mucosal contact.
- Wash applicator with mild soap and warm water after each use.
- Rotate application timing and frequency per prescriber instructions.
- 30g tube provides approximately 30 doses at 1 gram per application.
Prescriber determines application dose (typically 0.5–1 g per application) and frequency. Common approach:
- Initial daily application for 2–4 weeks.
- Maintenance: 2–3 times per week thereafter.
- Reassess symptom response and adjust frequency at follow-up visits.
- All dosing decisions are at the prescriber's discretion.
- Estradiol 0.03% (vaginal): Absorbed through vaginal mucosa; binds ERα and ERβ in vaginal epithelial, stromal, and urethral cells. Stimulates epithelial proliferation and maturation, restores glycogen content, promotes return of lactobacillus-dominant microbiome, lowers vaginal pH, and improves tissue elasticity and lubrication. ERβ activation in the urethral epithelium supports urinary symptom improvement. Systemic absorption at this concentration and typical application volumes is limited but non-zero.
Clinical Context: Indicated for GSM — vaginal dryness, dyspareunia, recurrent UTIs, urinary urgency related to estrogen-depleted atrophic change. The 30g tube size is appropriate for an initial treatment course (daily for 2–4 weeks) followed by transition to maintenance dosing. Clinical response is typically evident within 4–8 weeks of initiation. Progestogen co-prescribing for very-low-dose vaginal estrogen is at prescriber discretion per current guidelines and individual patient risk.
Contraindications:
- Estrogen-dependent malignancies, undiagnosed genital bleeding, active VTE/PE/arterial thromboembolism, active liver disease, pregnancy, hypersensitivity to estradiol or cream components.
Warnings & Precautions:
- Some systemic absorption — caution in patients where any systemic estrogen is contraindicated.
- Endometrial protection at prescriber discretion with very-low-dose local estrogen.
- Latex contraceptive incompatibility.
Drug Interactions:
- Minimal systemic absorption limits significant drug interactions; CYP3A4 considerations apply if systemic absorption increases. Latex barrier method degradation.
Common Side Effects: Vaginal discharge, local irritation, mild burning or pruritis, application site discomfort, headache.
Store at controlled room temperature (20–25°C / 68–77°F); do not freeze. Keep tube capped tightly, away from heat and light. Store out of reach of children. Observe the beyond-use date assigned by Genesis Compounding. Once opened, use within the timeframe specified on the compounding label.
How long will a 30g tube last?
At 1 gram per application, a 30g tube provides approximately 30 applications. If using 0.5 g per dose during maintenance, the tube may last up to 60 applications. Your prescriber or Genesis Compounding can confirm the specific gram-per-dose instruction for your prescription.
Do I need a progestogen with this vaginal cream?
Very-low-dose vaginal estradiol at this concentration generally does not require concurrent progestogen for endometrial protection per most guidelines. However, individual prescriber assessment is required based on your medical history and any prior endometrial conditions.
Is this FDA-approved?
This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding and is not FDA-approved as a finished compounded drug product.
Can this cream be used long-term?
Long-term use at the lowest effective frequency and dose is generally supported for symptomatic GSM in the absence of contraindications. Your prescriber will reassess ongoing need and tolerance at regular follow-up visits.
Should I expect discharge after using the cream?
Yes — vaginal discharge (cream residue) is expected, particularly after initial application. Wearing a panty liner may be helpful. If discharge becomes unusual in color, odor, or consistency, contact your prescriber.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.